BlueCare Discovery uses a high‑throughput platform to screen marine microalgae for bioactive metabolites that act on early biomarkers of chronic and neurodegenerative diseases. The company supplies these sustainably sourced compounds to nutraceutical, biopharmaceutical, dermo‑cosmetic, and animal‑health manufacturers for preventive health products.
Funding
Funding not disclosed
Founders
Product
Problem
Current preventive health strategies lack effective, environmentally sustainable sources of bioactive compounds that can target early physiological markers of chronic and neurodegenerative diseases. This limits the development of preventive and therapeutic agents that act before symptoms appear.
Solution
BlueCare Discovery leverages the vast biodiversity of marine microalgae to isolate and develop bioactive molecules for health applications. Its proprietary deep‑tech platform screens compounds selected by billions of years of evolution for efficacy against early disease markers. The company translates these molecules into nutraceuticals, biopharmaceuticals, dermo‑cosmetics, and animal‑health products aimed at preventing or treating chronic and neurodegenerative conditions such as Alzheimer’s disease. By focusing on marine biomimicry, BlueCare offers a renewable, low‑impact source of active ingredients that can be integrated into precision‑medicine approaches.
Target Audience
Primary customers include nutraceutical manufacturers, biopharmaceutical developers, dermo‑cosmetic companies, and animal‑health product firms seeking marine‑derived active ingredients for preventive health solutions.
Features
- High‑throughput screening pipeline that isolates and characterizes microalgal metabolites with activity on early physiological biomarkers
- Proprietary extraction and purification processes optimized for scalability and environmental sustainability
- Multi‑format product development pipeline covering nutraceutical, biopharmaceutical, dermo‑cosmetic, and veterinary applications
- Integration of marine biomimicry principles to enhance compound efficacy and safety profiles
- Partnerships with research institutions and industry partners to validate therapeutic potential in neurodegenerative disease models